ER-100 epigenetic therapy Clinical Trials (2026): 1 Studies for NAION( Non-arteritic Anterior Ischemic Optic Neuropathy) & Open Angle Glaucoma (OAG)
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
1 ER-100 epigenetic therapy clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 1 indication (including NAION( Non-arteritic Anterior Ischemic Optic Neuropathy) & Open Angle Glaucoma (OAG)) and 18 total planned enrollment. 1 ER-100 epigenetic therapy clinical trial is actively recruiting at 4 U.S. sites across 4 states. Most recent activity: NCT07290244 (Mar 2032).
Where to Participate: All ER-100 epigenetic therapy Trial Sites in the U.S. (4 sites across 4 states)
Every actively recruiting ER-100 epigenetic therapytrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| CA | Global Research Management, Inc. | Glendale91204 | NCT07290244 | Map |
| MA | Mass Eye and Ear | Boston02114 | NCT07290244 | Map |
| NY | Columbia University Irving Medical Center/Edward S. Harkness Eye Institute | New York10032 | NCT07290244 | Map |
| SC | Charleston Neuroscience Institute | Charleston29414 | NCT07290244 | Map |
ER-100 epigenetic therapy clinical trials at a glance: phase × recruitment status
| Phase | recruiting | Total |
|---|---|---|
| P1 | 1 | 1 |
Recruiting ER-100 epigenetic therapy clinical trials (1)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07290244 | Evaluating ER-100 for Safety in People With Glaucoma or Non-Arteritic Anterior Ischemic Optic Neuropathy (Optic Nerve Conditions) | P1 | Open Angle Glaucoma (OAG) | 18 | Mar 2026 |
All ER-100 epigenetic therapy trials (1)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07290244 | Evaluating ER-100 for Safety in People With Glaucoma or Non-Arteritic Anterior Ischemic Optic Neuropathy (Optic Nerve Conditions) | P1 | recruiting | 18 | Life Biosciences Inc. | Mar 2026 |
ER-100 epigenetic therapy clinical trials: frequently asked questions
- How many ER-100 epigenetic therapy clinical trials are there?
- 1 ER-100 epigenetic therapy clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants.
- Are ER-100 epigenetic therapy clinical trials recruiting in 2026?
- Yes — 1 ER-100 epigenetic therapy trial is actively recruiting in 2026, with 4 U.S. sites across 4 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is ER-100 epigenetic therapy being studied for?
- ER-100 epigenetic therapy is being studied for NAION( Non-arteritic Anterior Ischemic Optic Neuropathy), Open Angle Glaucoma (OAG). The trials are grouped by indication on this page.
- What phase is ER-100 epigenetic therapy in?
- ER-100 epigenetic therapy clinical trials span 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors ER-100 epigenetic therapy clinical trials?
- The lead sponsor across the most ER-100 epigenetic therapy trials is Life Biosciences Inc.. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming ER-100 epigenetic therapyas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: